Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Mohammed Razvi & Mark Lazarev. (2018) Optimization of biologic therapy in Crohn’s disease. Expert Opinion on Biological Therapy 18:3, pages 263-272.
Read now
Read now
Andrew S. Day, Steven T. Leach & Daniel A. Lemberg. (2017) An update on diagnostic and prognostic biomarkers in inflammatory bowel disease. Expert Review of Molecular Diagnostics 17:9, pages 835-843.
Read now
Read now
Pauliina Molander, Martti Färkkilä, Helena Kemppainen, Timo Blomster, Airi Jussila, Harri Mustonen & Taina Sipponen. (2017) Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα-blocking agents. Scandinavian Journal of Gastroenterology 52:3, pages 284-290.
Read now
Read now
Guillaume Pineton de Chambrun, Pierre Blanc & Laurent Peyrin-Biroulet. (2016) Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 10:8, pages 915-927.
Read now
Read now
Articles from other publishers (38)
Nai‐Yu Chen, Chiao‐Hsiung Chuang, Yu‐Ching Chang, Yea‐Huei Kao Yang, Peng‐Hsu Chen & Ching‐Lan Cheng. (2023)
Suboptimal Outcomes and Retreatment Rate of Patients With Crohn's Disease After Forced Discontinuation of Biologics: A Nationwide
Population‐Based
Study
. Clinical Pharmacology & Therapeutics 114:4, pages 914-921.
Crossref
Crossref
Alex Arenas, María José Moreta, Ingrid Ordás, Agnès Fernández-Clotet, Berta Caballol, Marta Gallego, Alejandro Vara, Rebeca Barastegui, Angel Giner, Cristina Prieto, Maria Carme Masamunt, Roberto Candia & Elena Ricart. (2023) De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice. Gastroenterología y Hepatología.
Crossref
Crossref
Nurulamin M Noor, Paula Sousa, Dominik Bettenworth, Fernando Gomollón, Triana Lobaton, Peter Bossuyt, Maria Jose Casanova, Nik S Ding, Gabriele Dragoni, Federica Furfaro, Patrick F van Rheenen, Maria Chaparro, Javier P Gisbert, Edouard Louis & Konstantinos Papamichail. (2023) ECCO Topical Review on Biological Treatment Cycles in Crohn’s Disease. Journal of Crohn's and Colitis 17:7, pages 1031-1045.
Crossref
Crossref
Remi Mahmoud, Edo H.J. Savelkoul, Bindia Jharap & Bas Oldenburg. (2023) Reply. Clinical Gastroenterology and Hepatology 21:7, pages 1967-1968.
Crossref
Crossref
Cong Dai, Min Jiang & Yu-Hong Huang. (2023) Anti-TNF Withdrawal in Inflammatory Bowel Disease With Endoscopic Healing and the Risk of Relapse. Clinical Gastroenterology and Hepatology 21:7, pages 1967.
Crossref
Crossref
Annemay M. H. Stoker, Leslie Logghe, Mirjam C. M. van der Ende-van Loon, Erik J. Schoon, Ramon-Michel Schreuder, Arnold Stronkhorst & Lennard P. L. Gilissen. (2023) Relapse rates after withdrawal versus maintaining biologic therapy in IBD patients with prolonged remission. Clinical and Experimental Medicine.
Crossref
Crossref
Cong Dai, Yi-Nuo Wang, Wen-Ning Tian, Yu-Hong Huang & Min Jiang. (2023) Long-term clinical outcomes after the discontinuation of anti-TNF agents in patients with inflammatory bowel disease: a meta-analysis. Revista Española de Enfermedades Digestivas.
Crossref
Crossref
Renske W.M. Pauwels, C. Janneke van der Woude, Daan Nieboer, Ewout W. Steyerberg, María J. Casanova, Javier P. Gisbert, Nick A. Kennedy, Charlie W. Lees, Edouard Louis, Tamás Molnár, Kata Szántó, Eduardo Leo, Steven Bots, Robert Downey, Milan Lukas, Wei C. Lin, Aurelien Amiot, Cathy Lu, Xavier Roblin, Klaudia Farkas, Jakob B. Seidelin, Marjolijn Duijvestein, Geert R. D’Haens, Annemarie C. de Vries, Annemarie C. de Vries, Renske W.M. Pauwels, C. Janneke van der Woude, Daan Nieboer, Ewout W. Steyerberg, Jasmijn A.M. Sleutjes, Marjolijn Duijvestein, Geert R. D’Haens, María J. Casanova, Javier P. Gisbert, Nick A. Kennedy, Charlie W. Lees, Edouard Louis, Tamás Molnár, Kata Szántó, Eduardo Leo, José M. García-Ortiz, Robert Downey, Alenka J. Brooks, Peter J. Hamlin, Shaji Sebastian, Alan J. Lobo, Milan Lukas, Wei C. Lin, Aurelien Amiot, Cathy Lu, Levinus (Leo) A. Dieleman, Xavier Roblin, Shomron Ben-Horin, Klaudia Farkas, Jakob B. Seidelin, Casper Steenholdt & Steven Bots. (2022) Prediction of Relapse After Anti–Tumor Necrosis Factor Cessation in Crohn’s Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies. Clinical Gastroenterology and Hepatology 20:8, pages 1671-1686.e16.
Crossref
Crossref
Guanglin Cui, Jon Florholmen & Rasmus Goll. (2022) Could Mucosal TNF Transcript as a Biomarker Candidate Help Optimize Anti-TNF Biological Therapy in Patients With Ulcerative Colitis?. Frontiers in Immunology 13.
Crossref
Crossref
Tatyana Kushner, Angelyn Fairchild, F. Reed Johnson, Bruce E. Sands, Uma Mahadevan, Sreedhar Subramanian, Ashwin Ananthakrishnan, Christina Ha & Meenakshi Bewtra. (2021) Women’s Willingness to Accept Risks of Medication for Inflammatory Bowel Disease During Pregnancy. The Patient - Patient-Centered Outcomes Research 15:3, pages 353-365.
Crossref
Crossref
Reezwana Chowdhury & Sunanda V Kane. (2022) Pregnancy and Crohn’s disease: concerns and assurance of medical therapy. Gastroenterology Report 10.
Crossref
Crossref
Taku Kobayashi. (2022) Stopping Anti-TNF in CD Remitters: Cons. Inflammatory Intestinal Diseases 7:1, pages 59-63.
Crossref
Crossref
Joo Hye Song, Eun Ae Kang, Soo-Kyung Park, Sung Noh Hong, You Sun Kim, Ki Bae Bang, Kyeong Ok Kim, Hong Sub Lee, Sang-Bum Kang, Seung Yong Shin, Eun Mi Song, Jong Pil Im & Chang Hwan Choi. (2021) Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study. Gut and Liver 15:5, pages 752-762.
Crossref
Crossref
Kara M. De Felice & Sunanda Kane. (2021) Safety of anti-TNF agents in pregnancy. Journal of Allergy and Clinical Immunology 148:3, pages 661-667.
Crossref
Crossref
Taku Kobayashi, Satoshi Motoya, Shiro Nakamura, Takayuki Yamamoto, Masakazu Nagahori, Shinji Tanaka, Tadakazu Hisamatsu, Fumihito Hirai, Hiroshi Nakase, Kenji Watanabe, Takayuki Matsumoto, Masanori Tanaka, Takayuki Abe, Yasuo Suzuki, Mamoru Watanabe, Toshifumi Hibi, Shingo Kato, Atsushi Maemoto, Minoru Matsuura, Ryosuke Sakemi, Makoto Sasaki, Tomoyuki Tsujikawa, Motohiro Esaki, Norimasa Fukata, Kazuya Kitamura, Sakiko Hiraoka, Ryota Hokari, Shunji Ishihara, Tsutomu Mizoshita, Yuji Naito, Fumio Omata, Masayuki Saruta & Takuya Yoshino. (2021) Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. The Lancet Gastroenterology & Hepatology 6:6, pages 429-437.
Crossref
Crossref
Joerg Mahlich, Melanie May, Chiara Feig, Vincent Straub & Renate Schmelz. (2021) Persistence With Biologic Therapy and Associated Costs of Patients With Inflammatory Bowel Disease: A German Retrospective Claims Data Analysis. Crohn's & Colitis 360 3:2.
Crossref
Crossref
Dan Turner, Amanda Ricciuto, Ayanna Lewis, Ferdinando D’Amico, Jasbir Dhaliwal, Anne M. Griffiths, Dominik Bettenworth, William J. Sandborn, Bruce E. Sands, Walter Reinisch, Jürgen Schölmerich, Willem Bemelman, Silvio Danese, Jean Yves Mary, David Rubin, Jean-Frederic Colombel, Laurent Peyrin-Biroulet, Iris Dotan, Maria T. Abreu & Axel Dignass. (2021) STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 160:5, pages 1570-1583.
Crossref
Crossref
Catarina Frias Gomes, Thomas P Chapman & Jack Satsangi. (2020) De-escalation of medical therapy in inflammatory bowel disease. Current Opinion in Pharmacology 55, pages 73-81.
Crossref
Crossref
Bing Zhang, Alakh Gulati, Omeed Alipour & Ling Shao. (2020) Relapse From Deep Remission After Therapeutic De-escalation in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Journal of Crohn's and Colitis 14:10, pages 1413-1423.
Crossref
Crossref
Pabitra Sahu, Sudheer K. Vuyyuru, Bhaskar Kante, Ashish Agarwal, Raju Sharma, Prasenjit Das, Rajesh Panwar, Saransh Jain, Sawan Bopanna, Govind Makharia, Saurabh Kedia & Vineet Ahuja. (2020) Relapse rate following withdrawal of anti-TNF therapy in patients with inflammatory bowel disease: A real-life cohort from northern India. Indian Journal of Gastroenterology 39:4, pages 388-397.
Crossref
Crossref
Joana Torres, Stefanos Bonovas, Glen Doherty, Torsten Kucharzik, Javier P Gisbert, Tim Raine, Michel Adamina, Alessandro Armuzzi, Oliver Bachmann, Palle Bager, Livia Biancone, Bernd Bokemeyer, Peter Bossuyt, Johan Burisch, Paul Collins, Alaa El-Hussuna, Pierre Ellul, Cornelia Frei-Lanter, Federica Furfaro, Christian Gingert, Paolo Gionchetti, Fernando Gomollon, Marien González-Lorenzo, Hannah Gordon, Tibor Hlavaty, Pascal Juillerat, Konstantinos Katsanos, Uri Kopylov, Eduards Krustins, Theodore Lytras, Christian Maaser, Fernando Magro, John Kenneth Marshall, Pär Myrelid, Gianluca Pellino, Isadora Rosa, Joao Sabino, Edoardo Savarino, Antonino Spinelli, Laurents Stassen, Mathieu Uzzan, Stephan Vavricka, Bram Verstockt, Janindra Warusavitarne, Oded Zmora & Gionata Fiorino. (2020) ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. Journal of Crohn's and Colitis 14:1, pages 4-22.
Crossref
Crossref
Thomas P Chapman, Catarina Frias Gomes, Edouard Louis, Jean-Frédéric Colombel & Jack Satsangi. (2020) De-escalation of immunomodulator and biological therapy in inflammatory bowel disease. The Lancet Gastroenterology & Hepatology 5:1, pages 63-79.
Crossref
Crossref
E. Yu. Chashkova, N. S. Korotayeva, E. E. Kunetsova, V. G. Gorokhova & E. V. Soboleva. (2019) Assessment of the State of Cell Membranes against the Background of Prolonged Use of Anticytokine Therapy in Patients with Ulcerative Colitis. Acta Biomedica Scientifica (East Siberian Biomedical Journal) 4:5, pages 84-90.
Crossref
Crossref
Antoine Petitcollin, Charlène Brochard, Laurent Siproudhis, Camille Tron, Marie‐Clémence Verdier, Florian Lemaitre, Camille Lucidarme, Guillaume Bouguen & Éric Bellissant. (2019) Pharmacokinetic Parameters of Infliximab Influence the Rate of Relapse After De‐Escalation in Adults With Inflammatory Bowel Diseases. Clinical Pharmacology & Therapeutics 106:3, pages 605-615.
Crossref
Crossref
Emilio J. Laserna-Mendieta & Alfredo J. Lucendo. (2019) Faecal calprotectin in inflammatory bowel diseases: a review focused on meta-analyses and routine usage limitations. Clinical Chemistry and Laboratory Medicine (CCLM) 57:9, pages 1295-1307.
Crossref
Crossref
Miles P. Sparrow, Gil Y. Melmed, Shane Devlin, Patricia Kozuch, Laura Raffals, Edward V. Loftus Jr, David T. Rubin, Brennan Spiegel, Leonard Baidoo, Brian Bressler, Adam Cheifetz, Peter Irving, Jennifer Jones, Gilaad G. Kaplan, Fernando Velayos & Corey A. Siegel. (2019) De‐escalating medical therapy in Crohn’s disease patients who are in deep remission: A RAND appropriateness panel. GastroHep 1:3, pages 108-117.
Crossref
Crossref
Fabiana Castiglione, Nicola Imperatore, Anna Testa, Giovanni Domenico De Palma, Olga Maria Nardone, Lucienne Pellegrini, Nicola Caporaso & Antonio Rispo. (2019) One‐year clinical outcomes with biologics in Crohn's disease: transmural healing compared with mucosal or no healing. Alimentary Pharmacology & Therapeutics 49:8, pages 1026-1039.
Crossref
Crossref
Rocío Sedano Muñoz, Rodrigo Quera Pino, Jaime Lubascher Correa, Gonzalo Pizarro Jofré & Daniela Simian Marín. (2019) Evaluación del retiro progresivo y/o la suspensión de la terapia anti-TNF-α en la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 42:2, pages 133-140.
Crossref
Crossref
Rocío Sedano Muñoz, Rodrigo Quera Pino, Jaime Lubascher Correa, Gonzalo Pizarro Jofré & Daniela Simian Marín. (2019) Evaluation of de-escalation of anti-TNF-α therapy in inflammatory bowel disease. Gastroenterología y Hepatología (English Edition) 42:2, pages 133-140.
Crossref
Crossref
Camille Lucidarme, Antoine Petitcollin, Charlène Brochard, Laurent Siproudhis, Marie Dewitte, Amandine Landemaine, Eric Bellissant & Guillaume Bouguen. (2018) Predictors of relapse following infliximab de‐escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring. Alimentary Pharmacology & Therapeutics 49:2, pages 147-154.
Crossref
Crossref
Catarina Frias Gomes, Jean-Frédéric Colombel & Joana Torres. (2018) De-escalation of Therapy in Inflammatory Bowel Disease. Current Gastroenterology Reports 20:8.
Crossref
Crossref
Clémence Legué, Charlène Brochard, Grégoire Bessi, Timothée Wallenhorst, Marie Dewitte, Laurent Siproudhis & Guillaume Bouguen. (2018) Outcomes of Perianal Fistulising Crohn’s Disease Following Anti-TNFα Treatment Discontinuation. Inflammatory Bowel Diseases 24:6, pages 1107-1113.
Crossref
Crossref
Ray K Boyapati, Joana Torres, Carolina Palmela, Claire E Parker, Orli M Silverberg, Sonam D Upadhyaya, Tran M Nguyen & Jean-Frédéric Colombel. (2018) Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease. Cochrane Database of Systematic Reviews 2018:5.
Crossref
Crossref
Catherine Reenaers, Jean-Yves Mary, Maria Nachury, Yoram Bouhnik, David Laharie, Matthieu Allez, Mathurin Fumery, Aurélien Amiot, Guillaume Savoye, Romain Altwegg, Martine Devos, Georgia Malamut, Arnaud Bourreille, Bernard Flourie, Philippe Marteau, Lucine Vuitton, Benoît Coffin, Stéphanie Viennot, Jérôme Lambert, Jean-Frédéric Colombel & Edouard Louis. (2018) Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn’s Disease in Sustained Remission. Clinical Gastroenterology and Hepatology 16:2, pages 234-243.e2.
Crossref
Crossref
Glen Doherty, Konstantinos H Katsanos, Johan Burisch, Matthieu Allez, Konstantinos Papamichael, Andreas Stallmach, Ren Mao, Ingrid Prytz Berset, Javier P Gisbert, Shaji Sebastian, Jarosław Kierkuś, Loris Lopetuso, Edyta Szymanska & Edouard Louis. (2018) European Crohn’s and Colitis Organisation Topical Review on Treatment Withdrawal [‘Exit Strategies’] in Inflammatory Bowel Disease. Journal of Crohn's and Colitis 12:1, pages 17-31.
Crossref
Crossref
Hang Hock Shim & Cynthia H. Seow. 2018. Treatment of Inflammatory Bowel Disease with Biologics. Treatment of Inflammatory Bowel Disease with Biologics
141
162
.
Jean-Frederic Colombel, Neeraj Narula & Laurent Peyrin-Biroulet. (2017) Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases. Gastroenterology 152:2, pages 351-361.e5.
Crossref
Crossref
N. A. Kennedy, B. Warner, E. L. Johnston, L. Flanders, P. Hendy, N. S. Ding, R. Harris, A. S. Fadra, C. Basquill, C. A. Lamb, F. L. Cameron, C. D. Murray, M. Parkes, I. Gooding, T. Ahmad, D. R. Gaya, S. Mann, J. O. Lindsay, J. Gordon, J. Satsangi, A. Hart, S. McCartney, P. Irving & C. W. Lees. (2016) Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. Alimentary Pharmacology & Therapeutics 43:8, pages 910-923.
Crossref
Crossref